Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Bevacizumab Plus Irinotecan (Camptosar) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

X
Trial Profile

Phase II Study of Bevacizumab Plus Irinotecan (Camptosar) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
  • Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Medulloblastoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 29 Oct 2010 Planned End Date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 29 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top